ロード中...
The use of integrase inhibitors in treatment-experienced patients
Raltegravir, the first approved HIV-1 integrase inhibitor, is able to block the strand transfer step of the HIV proviral DNA integration process into the cellular host DNA. The selected dosage for the pivotal phase III studies (subsequently approved by the regulatory agencies) was 400 mg bid by oral...
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2009
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3516826/ https://ncbi.nlm.nih.gov/pubmed/19959414 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2047-783X-14-S3-30 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|